Rohit Loomba, Ginger Clark, Jeff Teckman, Veeral Ajmera, Cynthia Behling, Mark Brantly, David Brenner, Jeanine D'Armiento, Michael W Fried, Janani S Iyer, Mattias Mandorfer, Don C Rockey, Monica Tincopa, Raj Vuppalanchi, Zobair Younossi, Aleksander Krag, Alice M Turner, Pavel Strnad
BACKGROUND: Alpha-1 antitrypsin liver disease (AATLD) occurs in a subset of patients with alpha-1 antitrypsin deficiency. Risk factors for disease progression and specific pathophysiologic features are not well known and validated non-invasive assessments for disease severity are lacking. Currently, there are no approved treatments for AATLD. AIMS: To outline existing understanding of AATLD and to identify knowledge gaps critical to improving clinical trial design and development of new treatments...
March 22, 2024: Alimentary Pharmacology & Therapeutics